Questioning How to Define the “Ultra-High-Risk” Subgroup of Neuroblastoma Patients
A. B. Demir1,2, Safiye Aktas2, Z. Altun2, P. Ercetin2, T. C. Aktas2, N. Olgun3
1Department of Basic Medical Sciences, Faculty of Medicine, Izmir University of Economics, Izmir, Turkey 2Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey 3Department of Clinical Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey
